RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This is how existing shareholders should be treatedFDA approved first injectable regimen few days ago, I don't suspect that would be classed as bad news as patients have to have low/stable viral loads before using the drug also I am not sure the efficacy wil be as good as current regimen and it seems to have many side effects.
Trogarzo is currently used as last line of defence because of long lasting efficacy and very mild adverse effects with rather small targeted cohorts so this new drug shouldn't change the sales meaningfully.
The good news is the industry is moving towards biweekly/monthly drugs as many PLWH prefer not to take bunch of drugs on a daily basis.